drugset / Trial / NCT01323959

Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults

NCT01323959 ↗

Phase 4 Completed 212 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelPrevention

Summary

This study will evaluate the persistence of immune response against diphtheria, tetanus, pertussis and poliomyelitis in healthy adults, 10 years after a booster dose, and also assess the immunogenicity and safety of another booster dose of BoostrixTM Polio.

Timeline

Start
2011-04-01
Primary completion
2012-03-01
Completion
2012-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject BoostrixTM Polio Vaccine — Intramuscular